Last updated on November 2019

The Safety Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors


Brief description of study

The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Clinical Study Identifier: NCT02660034

Find a site near you

Start Over

Virginia Cancer Specialists

Fairfax, VA United States
4.83miles
  Connect »